Biocon Wins MYR 300 Million Contract for Insulin from MoH, Malaysia

  • Posted by: Biocon Biologics

Biocon Q3 FY17 Net Profit Up 65% at Rs 171 Crore Revenue Rises 32% at Rs 1092 Crore; EBITDA Increases 57% to Rs 324 Crore

  • Posted by: Biocon Biologics

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Trastuzumab

  • Posted by: Biocon Biologics

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon’s Proposed Biosimilar Trastuzumab Phase 3 Data

  • Posted by: Biocon Biologics

Biocon Features in Asia IP Elite 2016 List

  • Posted by: Biocon Biologics

Biocon’s Novel Diabetes Education Initiative for Medical Practitioners ‘ABIDE’ Awarded by RSSDI

  • Posted by: Biocon Biologics

Biocon Collaborates with Healthcare Professionals for a Public Awareness Campaign on Diabetes Prevention & Management Across India

  • Posted by: Biocon Biologics

Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab

  • Posted by: Biocon Biologics

Mylan and Biocon Announce Regulatory Submission for Insulin Glargine Accepted for Review by European Medicines Agency

  • Posted by: Biocon Biologics

Biocon Ranked Among Global Top Ten Biotech Employers; The only Asian Company to Feature in 2016 Rankings Biocon moves up to No. 9 from No. 13 last year

  • Posted by: Biocon Biologics
Share